Tilak Healthcare will rely on medical representatives from Novartis France to inform ophthalmologists in France of this innovation and provide greater access to this solution.
Developed by physicians and video game professionals, OdySight is a concrete example of digital solutions to improve patient care.
By combining games and medical tests, the application allows close monitoring of patients with chronic ocular diseases (eg, AMD, diabetic macular edema, high myopia).
The user performs medical tests and then can progress through a puzzle game to test his cognitive and visual abilities.
In case of vision loss detected by the application, an alert is sent to the patient, inviting him to make an appointment with his ophthalmologist.
OdySight, as a fun and engaging application, motivates the patient to come back on a regular basis, and therefore, to do more visual tests, in a sustainable fashion, than are normally performed during a traditional care pathway.
Tilak is a videogame studio where people create mobile medical games for patients with chronic diseases.
vTv Therapeutics secures USD51m private placement for cadisegliatin Phase 3 study
AbbVie names new chief executive officer
SkinBioTherapeutics expands foot care products in AMEA with Dermatonics partnership
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
China accepts GSK's Shingrix application for at-risk adults
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults